CooperSurgical, Inc. Launches PGTai Technology Platform and ERPeak Endometrial Receptivity Test
CooperSurgical Fertility and Genomic Solutions
CooperSurgical Fertility and Genomic Solutions23 November 2018
The PGTai technology platform is a ground-breaking platform that harnesses the power of artificial intelligence (AI) and machine learning to improve PGT-A calling, interpretation, and reporting. Built on data of 1000+ biopsies that led to healthy babies, a vastly larger dataset for baseline than other available PGT-A software in use today, the PGTai technology platform provides robust data analysis, reporting and interpretation. To ensure the platform was ready for any clinical situation, sequencing data from 10,000+ embryos and 5 million data points were analysed by the PGTai technology platform and reviewed for accuracy in interpretation and reporting. This breakthrough improves accuracy of interpretation and reporting while removing subjectivity and avoiding transcription errors.
“As someone who has read tens of thousands of PGT-A results, I’m really excited about the impact that the PGTai technology platform will have on our labs. The PGTai technology platform project began as an initiative to simply improve our analytical process. As we reviewed our methods, it just didn’t make sense to me that we take a sophisticated approach like sequencing and reduce all of that data down to a simple image. With that in mind, and given recent advances in data science, it was clear to us that deploying machine learning and AI was the way to go,” said Mike Large PhD, Senior Director R&D for CooperSurgical Fertility and Genomic Solutions.
Processed on CooperSurgical’s custom-developed and validated platform, the new ERPeak endometrial receptivity test offers accurate and reliable detection of the receptivity status of a woman's endometrium, helping inform optimal embryo transfer timing. “The progress we’ve made in the last 15 years of embryo genetics, culminating with PGTai platform, have been truly impressive. That said, when we look at the SART data, we’re hard pressed to achieve pregnancy rates north of 60%. As we investigated opportunities to improve fertility outcomes, the endometrium was an obvious choice,” said Josh Blazek PhD, Senior Director R&D for CooperSurgical Fertility and Genomic Solutions, a CooperSurgical, Inc. business segment.
The ERPeak test adds to CooperSurgical Fertility and Genomic Solutions’ market leading preimplantation genetic testing (PGT) portfolio and reinforces CooperSurgical Fertility and Genomic Solutions’ position as the comprehensive provider of IVF laboratory and genetic testing solutions.
“As the leading company in PGT, we are excited to offer these new and innovative products to our customers. CooperSurgical Fertility and Genomic Solutions is committed to investing and innovating in the reproductive genetic testing space and these products represent the first of many exciting products that we have in the pipeline" said Tony Gordon PhD, VP Business Development for CooperSurgical Fertility and Genomic Solutions.
The PGTai technology platform and ERPeak endometrial receptivity test is available to order in North America. Both will be available internationally starting January 2019.